Ventrus Biosciences (VTUS) Trading Near Cash Value Says Cantor Fitzgerald
Tweet Send to a FriendGet Alerts VTUS Hot Sheet
Price: $2.66 +0.76%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VTUS Now!
Analysts at Cantor Fitzgerald continue to see value in shares of Ventrus Biosciences (NASDAQ: VTUS), though the stock has declined 75 percent this year.
"VTUS has traded down to practically cash value. At the current stock price of $2.06 and 13M shares outstanding, the market cap is approximately $26.8M, whereas the company has a cash balance of $23.6M (and will not need financing until late 2013, in our view)," said analyst Irina Rivkind.
She thinks the market is assigning minimal value to the company's Phase III asset in anal fissure, which should be market-ready by end of 2014.
"Management plans to report the results of its anal fissure market research in a few weeks, which we believe should re-energize the stock to some extent," added Rivkind.
Cantor Fitzgerald maintained a Buy on Ventrus Biosciences (NASDAQ: VTUS) with a price target of $7.00. The stock was upgraded from Hold on August 10th.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $2.06 yesterday, with a 52 week range of $1.99-$13.53.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"VTUS has traded down to practically cash value. At the current stock price of $2.06 and 13M shares outstanding, the market cap is approximately $26.8M, whereas the company has a cash balance of $23.6M (and will not need financing until late 2013, in our view)," said analyst Irina Rivkind.
She thinks the market is assigning minimal value to the company's Phase III asset in anal fissure, which should be market-ready by end of 2014.
"Management plans to report the results of its anal fissure market research in a few weeks, which we believe should re-energize the stock to some extent," added Rivkind.
Cantor Fitzgerald maintained a Buy on Ventrus Biosciences (NASDAQ: VTUS) with a price target of $7.00. The stock was upgraded from Hold on August 10th.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $2.06 yesterday, with a 52 week range of $1.99-$13.53.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Needham & Company Remains on Sidelines wth Applied Materials (AMAT) Post Q2
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
